ILC Therapeutics: against COVID-19 Company
Entity: ILC Therapeutics
Category: Treatment Development
Description: ILC Therapeutics™ Ltd is an early stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Cancer, Atopic Dermatitis and Psoriasis.
Project: rIFN alpha14
Summary: Preliminary data shows that the ILC Therapeutics’ rIFN alpha14 may have significant potential to prevent COVID-19 induced Acute Respiratory Distress Syndrome (ARDS). In vitro the molecule enhances NK cell activity while reducing Neutrophil activation and chemotaxis. ILC Therapeutics are actively exploring partnering and funding opportunities to take this drug candidate into Phase 2a trials in early 2021.
Category: Treatment Development
Description: ILC Therapeutics™ Ltd is an early stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Cancer, Atopic Dermatitis and Psoriasis.
Project: rIFN alpha14
Summary: Preliminary data shows that the ILC Therapeutics’ rIFN alpha14 may have significant potential to prevent COVID-19 induced Acute Respiratory Distress Syndrome (ARDS). In vitro the molecule enhances NK cell activity while reducing Neutrophil activation and chemotaxis. ILC Therapeutics are actively exploring partnering and funding opportunities to take this drug candidate into Phase 2a trials in early 2021.
Technology:
Treatment Development
Headquarters:
United Kingdom
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership